1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Innova Captab Limited

Innova Captab Limited

996.50
INR
+16.30
(+1.66%)
26.91EPS
36.36P/E
55.99BMarket Cap
Nov 06Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
86.25
94.6
71.57
139.76
161.71
212.99
215.71
280.28
305.6
Basic EPS, GAAP
6.11
8.49
6.03
11.18
11.87
18.66
22.41
24.63
26.91
Free Cash Flow per Basic Share
1.88
4.64
3.99
-3.67
-2.07
-27.89
-18.99
8.42
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
2
- -
Book Value per Share
5.33
13.33
25.31
36.45
48.32
145.2
167.66
190.61
- -
Tangible Book Value per Share
2.31
10.34
25.23
33.46
45.27
142.12
164.61
187.44
- -
Basic Weighted Avg Shares
57
57
57
57
57
51
57
57
57
Sales/Revenue/Turnover
4,936
5,413
4,096
7,998
9,254
10,770
12,344
16,039
17,493
Operating Margin (%)
10.94
13.17
12
11.09
11.36
13.14
13.4
11.67
12.21
Depreciation Expense
107
101
56
75
111
160
248
452
458
Net Income, GAAP
350
486
345
640
680
943
1,283
1,409
1,540
Effective Tax Rate (%)
27.16
28.34
25.56
25.39
25.97
27.16
25
25.15
24.71
Profit Margin (%)
7.08
8.98
8.42
8
7.34
8.76
10.39
8.79
8.8
Working Capital
-555
-161
553
845
1,649
3,143
3,501
4,284
- -
LT Debt
271
127
64
679
1,356
2,105
2,449
2,158
- -
Total Equity
305
763
1,448
2,086
2,765
8,309
9,594
10,908
- -
Return on Invested Capital (%)
- -
39.05
21.93
22.12
16.91
13.01
10.32
10.28
- -
Return on Capital (%)
- -
40.98
22.32
22.71
17.8
13.81
10.95
11.23
- -
Return on Common Equity (%)
- -
91.02
31.21
36.19
28.02
17.04
14.33
13.75
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,279
- -
LT Borrowings
- -
2,148
- -
LT Finance Leases
- -
10
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
57
57
57
Market Capitalization
41,208
39,477
55,992

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
9,230
- -
Cash, Cash Equivalents & STI
- -
445
- -
Accounts Receivable, Net
- -
4,373
- -
Inventories
- -
2,833
- -
Total Current Liabilities
- -
4,946
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,279
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.25%
13.69%
Free Cash Flow
- -
137.13%
-144.33%
Net Income, GAAP
- -
35.26%
9.87%
Sales/Revenue/Turnover
- -
34.38%
29.93%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2,943
3,182
3,165
3,147
12,344
2026
3,515
3,804
4,503
4,478
16,039
2027
4,709
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5.15
6.12
5.97
5.17
22.41
2026
5.42
5.18
7.37
6.65
24.63
2027
7.71
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
2
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Vinay Kumar Lohariwala
Full Time Employees
2,301
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Plot No.320, Industrial Area Panchkula HA India 134113
IPO Date
Dec 29, 2023
Website
innovacaptab.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Innova Captab Limited, an integrated pharmaceutical company incorporated in 2005 and headquartered in Panchkula, India, engages in research, development, manufacturing, distribution, and marketing of pharmaceutical products across India and internationally. The company operates three primary business segments: contract development and manufacturing organization (CDMO) services, which rank it as the second-largest domestic formulations CDMO and encompass over 2,400 products in diverse dosage forms including oral solids, oral liquids, dry syrups, injectables, modified and sustained release forms, and tablets-in-capsules for acute and chronic therapies; domestic branded generics marketed through a network of over 5,000 stockists and distributors reaching 150,000 Indian retailers, featuring therapeutic categories such as cephalosporins, proton pump inhibitors, anticholinergic and heparin NSAIDs, analgesics and antipyretics, anticold and antiallergics, antiemetics, antidiabetics, anticonvulsants and antipsychotics, bladder and prostate disorder treatments, antifungals, anthelmintics and antivirals, anticholinergics, anti-asthmatics, and bronchodilators in tablets, capsules, dry syrups, dry powder injections, ointments, and liquid orals; and international branded generics with over 200 products registered with authorities and presence in more than 15 countries. Recent major developments include the acquisition of Sharon Bio-Medicine Limited to bolster CDMO capabilities and regulated market exposure in regions such as Canada, the United Kingdom, Australia, and Central and South America; commissioning of a new greenfield manufacturing facility in Kathua, Jammu, achieving commercial operations by late 2024 with ongoing contributions to revenue; purchase of approximately 20 bighas of land in Baddi, Himachal Pradesh, for ₹19.5 crore in August 2025 to support future capacity expansion; and successful regulatory inspections at its cephalosporin plant in Baddi by the UK-MHRA and Jammu facility by Ukraine's State Service of Medicines and Drugs Control.